PressJune 14, 2024 Largest Study of Psychedelic Medicine, with 11,441 Mindbloom Clients, Demonstrates Effectiveness and Safety of Guided At-Home Ketamine Therapy
PressJune 13, 2024 Filament Health Announces Closing of Warrant Exercise, Note Conversion and Concurrent Private Placement of Common Shares
PressJune 12, 2024 Mindbio Therapeutics Reports Secondary Data: Improvement of Psychological Outcomes & Safety Results in Depressed Patients from Phase 2A Depression Trial
PressJune 12, 2024 Revive Therapeutics Provides Update on FDA Type C Meeting for Clinical Study of Bucillamine to Treat Long COVID
PressJune 11, 2024 Cybin Appoints Dr. Atul Mahableshwarkar M.D., as Senior Vice President, Clinical Development
PressJune 11, 2024 Revive Therapeutics Provides Update From FDA Meeting for Long COVID Diagnostic Product
PressJune 11, 2024 Clearmind Medicine Revolutionizes the $13 Billion NonAlcoholic Beverages Market with its Psychedelic-Based Drink
PressJune 11, 2024 Optimi Health Completes First International Shipment of MDMA to Israel and Secures CBSA Exporters Authorization ID
PressJune 7, 2024 Numinus Wellness Comments on FDA Advisory Committee Meeting for Investigational MDMA-Assisted Therapy for PTSD
PressJune 7, 2024 Silo Pharma Announces Successful Production of its SP-26 Ketamine Implant for Fibromyalgia
PressJune 7, 2024 Red Light Holland Announces Completion of Full Psilocybin Extraction Report with PharmAla
PressJune 5, 2024 Silo Pharma Announces $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
PressJune 4, 2024 Silo Pharma Submits Pre-Investigational New Drug Application to FDA for SPC-15 as a Treatment for PTSD and Anxiety
PressJune 3, 2024 Filament Health Announces Warrant Exercise and Note Conversion by Negev Capital and Concurrent Private Placement of Common Shares to Benjamin Lightburn, Chief Executive Officer
PressJune 3, 2024 Filament Health Announces Authorization of Phase 2 Clinical Trial for PEX010 in the Treatment of Methamphetamine Use Disorder
PressJune 3, 2024 Wesley Ramjeet to Join Lobe Sciences’ Board of Directors, Bringing Decades of Strategic Financial Expertise
